

Laeovate[®]

(BETAMETHASONE VALERATE)

COMPOSITION:

Laeovate[®] Cream contains: Betamethasone (as valerate) 0.1% w/w in a dermatological cream base.

Laeovate[®] Ointment contains: Betamethasone (as valerate) 0.1% w/w in a bland paraffin base.

INDICATIONS:

Laeovate[®] is indicated in various skin disorders where anti-inflammatory and antiallergic effects are desired. It is used for the management of moderate to severe steroid-responsive inflammatory and allergic skin disorders, where the presence or possibility of infection does not exist.

It is also used for the relief of symptoms and for the suppression of signs of skin disorders where less potent medication is ineffective.

Laeovate is used in cases of severe inflammatory skin disorders such as eczema, psoriasis, atopic dermatitis, contact dermatitis and intertrigo unresponsive to less potent corticosteroids.

In addition to the above skin disorders, **Laeovate[®]** often produces dramatic suppression of skin diseases, such as infantile eczema, dermatitis herpetiformis, seborrhoeic dermatitis, neuro-dermatitis and some form of psoriasis in which inflammation is a prominent feature.

DIRECTIONS FOR USE:

Laeovate[®] is applied topically by gentle massage to the affected parts. The preparation is applied thinly 2-3 times daily on the affected parts reducing the frequency of application as the condition responds or as directed by the physician.

PRECAUTIONS, WARNINGS AND ADVERSE EFFECTS:

1. **Laeovate[®]** should not be applied to large areas, when the skin is broken or under occlusive dressings since it may be absorbed in sufficient amount to cause systemic toxicity.

2. **Laeovate[®]** is contraindicated in patients with untreated bacterial, fungal and viral skin lesions as its use may result in exacerbation of the skin condition.

3. The adverse effects occasionally associated with the preparation include thinning of the skin, spread and worsening of untreated infection, mild depigmentation and increased hair growth at the site of application.

4. **Laeovate[®]** should not be applied to ulcers of the leg and long term topical use is best avoided, especially in children. In addition it should not be used for treatment of rosacea and should also not be used indiscriminately for pruritus.

PHARMACOLOGICAL PROPERTIES:

Laeovate[®] contains Betamethasone, a corticosteroid with Strong anti-inflammatory and antiallergic properties. Betamethasone exerts its anti-inflammatory effects by inhibiting cyclo-oxygenase enzymes involved in the biosynthesis of prostaglandins.

Betamethasone may be absorbed topically especially if applied to large areas of thin skin or broken skin or to raw surface.

Laeovate[®] combines the essential anti-inflammatory and antiallergic properties of Betamethasone with the ease of application and comfort of product formulation making it safe, fine and suitable for topical application.

LEGAL CATEGORY : Prescription Only Medicines (POM).

STORAGE CONDITIONS: Store in a dry place below 30°C.

Protect from light. Keep all medicines out of reach of children.

SHELF LIFE : As per the product label.

PRESENTATION:

Laeovate[®] Cream: 15g in collapsible tubes in a unit box.

Laeovate[®] Ointment: 15g in collapsible tubes in a unit box.

LAST REVIEW: July 2017

LICENCE HOLDER: LABORATORY & ALLIED LTD



Manufactured by:
Laboratory & Allied Ltd.
Plot No. 20B/10349, Mumbasa Road,
P.O. Box 41875, Nairobi, Kenya

LTL016-00